A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer
Public ClinicalTrials.gov record NCT05483868. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) to Determine the Feasibility and Safety of Intratumoral Injection With or Without Intramural Injection in Subjects With Bladder Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The main objectives of this study are to determine the feasibility and safety of Belzupacap Sarotalocan (AU-011, bel-sar) treatment of bladder cancer utilizing focal injections with or without laser application.
Study identification
- NCT ID
- NCT05483868
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 55 participants
Conditions and interventions
Conditions
Interventions
- AU-011 Drug
- AU-011 in Combination with Medical Laser Adminstration Combination Product
- AU-011 in Combination with Medical Laser Administration Combination Product
Drug · Combination Product
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 25, 2022
- Primary completion
- Feb 28, 2027
- Completion
- Feb 28, 2027
- Last update posted
- Aug 5, 2026
2022 – 2027
United States locations
- U.S. sites
- 13
- U.S. states
- 8
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arkansas Urology | Little Rock | Arkansas | 72211 | — |
| Tower Urology | Los Angeles | California | 90048 | — |
| Saint John's Cancer Institute | Santa Monica | California | 90404 | — |
| Colorado Clinical Research | Lakewood | Colorado | 80228 | — |
| Montefiore Medical Center | The Bronx | New York | 10461 | — |
| UPMC Hillman Cancer Center | Pittsburgh | Pennsylvania | 15232 | — |
| Carolina Urologic Research Center | Myrtle Beach | South Carolina | 29272 | — |
| Urology Associates, P.C. | Nashville | Tennessee | 37209 | — |
| Urology Clinics of North Texas | Dallas | Texas | 75251 | — |
| Baylor College of Medicine | Houston | Texas | 77030 | — |
| The University of Texas San Antonio | San Antonio | Texas | 78229 | — |
| Urology San Antonio/USA Clinical Trials | San Antonio | Texas | 78229 | — |
| The Urology Place | San Antonio | Texas | 78240 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05483868, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 5, 2026 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05483868 live on ClinicalTrials.gov.